Investing.com - Sarepta Therapeutics Inc. (NASDAQ:SRPT)股价周五下跌13%,此前欧洲监管机构建议不批准该公司用于治疗杜氏肌营养不良症的基因疗法Elevidys。 欧洲药品管理局的药物咨询委员会(CHMP)周五宣布,拒绝批准Elevidys用于治疗3至7岁能够行走的儿童。这种疗法在美国以外由罗氏控股(Roche Holding AG) (...
Source LinkInvesting.com - Sarepta Therapeutics Inc. (NASDAQ:SRPT)股价周五下跌13%,此前欧洲监管机构建议不批准该公司用于治疗杜氏肌营养不良症的基因疗法Elevidys。 欧洲药品管理局的药物咨询委员会(CHMP)周五宣布,拒绝批准Elevidys用于治疗3至7岁能够行走的儿童。这种疗法在美国以外由罗氏控股(Roche Holding AG) (...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.